Ticlopidine: Difference between revisions
ClaireLewis (talk | contribs) (Created page with "==Administration== *Type: Antiplatelet *Dosage Forms: *Routes of Administration: Oral *Common Trade Names: Ticlid ==Adult Dosing== *250mg PO BID ==Pediatric Dosing== ''S...") |
Elcatracho (talk | contribs) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 44: | Line 44: | ||
==See Also== | ==See Also== | ||
*[[Antiplatelet | *[[Antiplatelet medications]] | ||
*[[Antiplatelet agent reversal]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Latest revision as of 02:48, 6 March 2021
Administration
- Type: Antiplatelet
- Dosage Forms:
- Routes of Administration: Oral
- Common Trade Names: Ticlid
Adult Dosing
- 250mg PO BID
Pediatric Dosing
Safety/efficacy not established
Special Populations
- Pregnancy Rating: B
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing:
- Hepatic dosing: may have increased bleeding risk
Contraindications
- Allergy to class/drug
- Hematopoietic disorders (e.g. neutropenia, thrombocytopenia, or past history of TTP or aplastic anemia)
- Active bleeding
- Severe liver disease
Adverse Reactions
Serious
- Aplastic anemia, pancytopenia, agranulocytosis, pancytopenia, thrombocytopenia, neutorpenia, TTP
Common
- Rash
- Nausea, diarrhea, abdominal pain
- Hemorrhage
- Leukopenia
- Dizziness
Pharmacology
- Half-life: 4-5 days
- Metabolism: Hepatic
- Excretion: Mostly renal
Mechanism of Action
- Prevents ADP from stimulating platelet-fibrinogen binding, blocking platelet aggregation